Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy

15 Dec 2004

Abstract excerpt

Spinal muscular atrophy (SMA) is a frequent recessive autosomal disorder. It is caused by mutations or deletion of the telomeric copy of the survival motor neuron (SMN) gene, leading to depletion in SMN protein levels. The treatment rationale for SMA is to halt or delay the degeneration of motor neurons, but to date there are no effective drug treatments for this disease. We have previously demonstrated that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Congenital Anomalies and Fetal Surgery
Share to Neurogenetic and Muscular Disorders Research
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15599397
DOI: 10.1172/jci22922

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophyPMID 15599397Read ↗

Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and ChallengesSemantic proximity Read ↗

CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophySemantic proximity Read ↗

Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice.Semantic proximity Read ↗

Decreasing Disease Severity in Symptomatic, <i>Smn</i> <sup>−/−</sup> ; <i>SMN2</i> <sup>+/+</sup> , Spinal Muscular Atrophy Mice Following scAAV9-SMN DeliverySemantic proximity Read ↗

The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophySemantic proximity Read ↗

Spinal muscular atrophy: from tissue specificity to therapeutic strategiesSemantic proximity Read ↗

Development of a Gene Therapy Strategy for the Restoration of Survival Motor Neuron Protein Expression: Implications for Spinal Muscular Atrophy TherapySemantic proximity Read ↗

Therapeutic advances in 5q-linked spinal muscular atrophy.Semantic proximity Read ↗

Efficacy and preliminary safety assessment of EXG001-307 AAV gene therapy for spinal muscular atrophySemantic proximity Read ↗

Animal models of spinal muscular atrophy.Semantic proximity Read ↗

Defining the therapeutic window in a severe animal model of spinal muscular atrophy.Semantic proximity Read ↗

Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.